Ultragenyx Stock Total Debt
| RARE Stock | USD 48.13 0.77 1.63% |
Ultragenyx fundamentals help investors to digest information that contributes to Ultragenyx's financial success or failures. It also enables traders to predict the movement of Ultragenyx Stock. The fundamental analysis module provides a way to measure Ultragenyx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ultragenyx stock.
As of November 28, 2024, Total Debt To Capitalization is expected to decline to 0.03. Ultragenyx | Total Debt |
Ultragenyx Company Total Debt Analysis
Ultragenyx's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Ultragenyx Total Debt | 43.17 M |
Most of Ultragenyx's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ultragenyx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ultragenyx Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Ultragenyx is extremely important. It helps to project a fair market value of Ultragenyx Stock properly, considering its historical fundamentals such as Total Debt. Since Ultragenyx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ultragenyx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ultragenyx's interrelated accounts and indicators.
Click cells to compare fundamentals
Ultragenyx Total Debt Historical Pattern
Today, most investors in Ultragenyx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ultragenyx's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ultragenyx total debt as a starting point in their analysis.
Ultragenyx Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Ultragenyx Net Debt
Net Debt |
|
Based on the latest financial disclosure, Ultragenyx has a Total Debt of 43.17 M. This is 98.43% lower than that of the Biotechnology sector and 86.71% lower than that of the Health Care industry. The total debt for all United States stocks is 99.19% higher than that of the company.
Ultragenyx Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ultragenyx's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ultragenyx could also be used in its relative valuation, which is a method of valuing Ultragenyx by comparing valuation metrics of similar companies.Ultragenyx is currently under evaluation in total debt category among its peers.
Ultragenyx Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ultragenyx from analyzing Ultragenyx's financial statements. These drivers represent accounts that assess Ultragenyx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ultragenyx's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.4B | 8.4B | 5.7B | 3.2B | 3.5B | 2.4B | |
| Enterprise Value | 2.0B | 7.8B | 5.4B | 3.1B | 3.3B | 2.3B |
Ultragenyx ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ultragenyx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ultragenyx's managers, analysts, and investors.Environmental | Governance | Social |
Ultragenyx Institutional Holders
Institutional Holdings refers to the ownership stake in Ultragenyx that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ultragenyx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ultragenyx's value.| Shares | Rock Springs Capital Management Lp | 2024-06-30 | 1.9 M | Millennium Management Llc | 2024-06-30 | 1.9 M | Vestal Point Capital Lp | 2024-06-30 | 1.8 M | Deutsche Bank Ag | 2024-06-30 | 1.8 M | Baker Bros Advisors Lp | 2024-09-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Alliancebernstein L.p. | 2024-06-30 | 1.5 M | Amvescap Plc. | 2024-06-30 | 1.3 M | Alyeska Investment Group, L.p. | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 9.9 M | Blackrock Inc | 2024-06-30 | 5.6 M |
Ultragenyx Fundamentals
| Return On Equity | -2.9 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (1.07) % | ||||
| Operating Margin | (0.95) % | ||||
| Current Valuation | 3.79 B | ||||
| Shares Outstanding | 92.34 M | ||||
| Shares Owned By Insiders | 3.62 % | ||||
| Shares Owned By Institutions | 97.51 % | ||||
| Number Of Shares Shorted | 3.35 M | ||||
| Price To Earning | (6.90) X | ||||
| Price To Book | 12.61 X | ||||
| Price To Sales | 8.50 X | ||||
| Revenue | 434.25 M | ||||
| Gross Profit | (370.78 M) | ||||
| EBITDA | (516.45 M) | ||||
| Net Income | (606.64 M) | ||||
| Cash And Equivalents | 542.8 M | ||||
| Cash Per Share | 7.75 X | ||||
| Total Debt | 43.17 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 3.76 X | ||||
| Cash Flow From Operations | (474.81 M) | ||||
| Short Ratio | 4.01 X | ||||
| Earnings Per Share | (6.45) X | ||||
| Price To Earnings To Growth | (0.24) X | ||||
| Target Price | 92.43 | ||||
| Number Of Employees | 1.28 K | ||||
| Beta | 0.58 | ||||
| Market Capitalization | 4.44 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | (3.39 B) | ||||
| Working Capital | 451.75 M | ||||
| Current Asset | 416.79 M | ||||
| Current Liabilities | 50.43 M | ||||
| Net Asset | 1.49 B |
About Ultragenyx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ultragenyx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultragenyx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultragenyx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:Check out Ultragenyx Piotroski F Score and Ultragenyx Altman Z Score analysis. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.45) | Revenue Per Share 6.015 | Quarterly Revenue Growth 0.423 | Return On Assets (0.24) | Return On Equity (2.90) |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.